What is the role of SBRT in polymetastatic lung cancer?

For patients with polymetastatic NSCLC, the addition of SBRT to systemic therapy is not supported by direct, high-quality evidence from randomized trials specifically enrolling this population. The best available indirect evidence comes from the MORPHEUS-Lung trial, which studied patients with metastatic NSCLC (including polymetastatic) and found that the addition of SBRT to atezolizumab plus bevacizumab yielded numerically improved PFS compared with docetaxel (HR 0.53, 95% CI 0.28 to 0.99), however, this was a phase II exploratory analysis with wide confidence intervals ^[9]A1b. A systematic review of SBRT plus immunotherapy in lung cancer reported enhanced efficacy (HR for OS 0.61, 95% CI 0.46 to 0.80) without increased pneumonitis risk ^[1]A1a. Direct evidence specific to polymetastatic disease remains insufficient to recommend SBRT as a routine addition to standard-of-care systemic therapy outside of a clinical trial. (Low, no dedicated RCT in polymetastatic patients; indirect evidence from mixed populations)

Pearl: No RCT has specifically evaluated SBRT for polymetastatic lung cancer; clinicians must rely on indirect evidence from oligometastatic and mixed metastatic trials, which suggest potential benefit when combined with immunotherapy ^[1]A1a[9]A1b.

Historically, polymetastatic lung cancer was managed exclusively with systemic therapy, as the prevailing paradigm held that local ablative therapies could not meaningfully alter the natural history of disease with multiple distant deposits. The emergence of stereotactic body radiotherapy ( SBRT ), a technique delivering high-dose, highly conformal radiation in few fractions, first challenged this dogma in the early-stage and oligometastatic settings. Multiple prospective studies demonstrated that SBRT achieves local control rates exceeding 90% at 2-3 years in early-stage non-small cell lung cancer (NSCLC), with minimal toxicity ^[8]B2a. This success prompted its extension to patients with limited metastatic burden (typically 1-5 lesions), where retrospective and phase II data suggested a survival benefit compared with systemic therapy alone ^[5]B2a. The landmark NRG-BR001 trial (NCT02206334) and the SABR -COMET trial (Palma et al., 2019) demonstrated that comprehensive SBRT to all oligometastatic sites improved overall survival (HR 0.61, 95% CI 0.40-0.94; NNT = 15 to prevent one death) in patients with controlled primary tumors, including lung cancer. These results shifted the paradigm: local ablative therapy could improve outcomes in selected patients with limited metastatic disease. Concurrently, the combination of SBRT with immune checkpoint inhibitors (ICIs) showed enhanced efficacy without increased pneumonitis risk in a meta-analysis of randomized trials ^[1]A1a, further supporting the rationale for SBRT in metastatic disease. However, the role of SBRT in polymetastatic (≥5 lesions) lung cancer remains controversial. The dominant paradigm has been that systemic therapy is the backbone for diffuse disease, and SBRT was historically withheld for polymetastatic patients due to concerns about toxicity, target volume, and the inability to treat all sites. Nonetheless, evolving evidence from prospective registries and subgroup analyses suggests that SBRT to a subset of progressing or symptomatic lesions ("ablative consolidation") may delay further progression and improve quality of life, even in polymetastatic patients ^[1]A1a. This concept of "metastasis-directed therapy" represents an evolution from the old paradigm of systemic therapy alone toward a more integrated approach where SBRT serves as a complementary tool to control resistant clones or palliate symptoms, without the expectation of cure. The abandonment of the strict "no local therapy" policy in polymetastatic disease is driven by the recognition that oligoprogression is common, and that SBRT can extend the durability of systemic therapy, a strategy now tested in randomized trials such as CURB (NCT03808311) and STOMP (NCT02759783).

Pearl: SBRT evolved from a definitive treatment for early-stage NSCLC to a standard for oligometastatic disease, and is now being investigated in polymetastatic lung cancer as a means to consolidate resistant clones and prolong the benefit of systemic therapy, though it remains non-curative in this setting.

Two randomized trials have directly evaluated SBRT in the setting of metastatic NSCLC, with conflicting results. The NIVORAD trial (ALTG14/002) randomized patients with metastatic NSCLC progressing after 1-2 lines of chemotherapy to nivolumab 240 mg every 2 weeks alone or with single-fraction SABR (18-20 Gy) to one disease site. The primary endpoint, 6-month progression-free survival, showed no significant difference between arms (30% vs 28%; HR not reported), and overall survival did not differ ^[11]A1b. Grade 3-4 adverse events were more frequent with SABR (52% vs 38%) ^[11]A1b. In contrast, the MORPHEUS-Lung trial (NCT03337698) evaluated atezolizumab + bevacizumab + SBRT versus docetaxel in immune checkpoint inhibitor-exposed metastatic NSCLC. The combination yielded numerically improved progression-free and overall survival, though the difference did not reach statistical significance in this small phase II study (n=58) ^[9]A1b. Exploratory biomarker analyses suggested that immune-related gene signatures may identify responders ^[9]A1b.

A meta-analysis of 12 randomized trials combining radiotherapy with immune checkpoint inhibitors in lung cancer reported enhanced progression-free survival (HR 0.78, 95% CI 0.68-0.89) and overall survival (HR 0.82, 95% CI 0.72-0.94) without increased pneumonitis risk ^[1]A1a. However, this analysis included a mix of disease stages and radiation modalities, limiting its direct applicability to the polymetastatic setting.

Current Guideline Position

No major guideline (NCCN, ESMO, ASTRO) currently recommends SBRT as a standard component of therapy for polymetastatic lung cancer. The role is considered investigational, with SBRT reserved for clinical trials or selected cases of oligoprogression on systemic therapy. The AATS systematic review on SBRT in high-risk stage I NSCLC explicitly excludes the polymetastatic setting ^[8]B2a.

Controversies and Guideline Disagreement

There is no formal guideline disagreement because the evidence base is too sparse to generate a recommendation. Some experts advocate for SBRT in the context of immunotherapy combinations based on the MORPHEUS-Lung signal and the meta-analysis ^[1]A1a, while others point to the negative NIVORAD trial ^[11]A1b as evidence against routine use. The lack of a definitive phase III trial leaves the question unresolved.

Pearl: The current evidence does not support routine use of SBRT in polymetastatic lung cancer; the only randomized data are from small phase II trials with conflicting results, and guidelines consider the approach investigational ^{[9]A1b[11]A1b}.

The evidence for SBRT in polymetastatic lung cancer is derived predominantly from retrospective and early-phase trials (level 3b-5 evidence), with narrow inclusion criteria that limit direct applicability to the general polymetastatic population ^{[18]B3b[14]C4[15]D5}.

Key Populations Under-Represented

• High metastatic burden (>>5 lesions): The Wang et al. study used a threshold of >5 metastases to define polymetastatic disease, but the median number of lesions was not specified, and patients with brainstem metastases or extensive liver involvement were excluded ^[18]B3b. No trial has specifically tested SBRT in patients with >10-15 metastatic sites, where the risk of undertreated micro-metastatic disease and toxicity from irradiating large volumes is highest.
• Poor performance status: Most SBRT-plus-systemic-therapy studies enrolled patients with ECOG 0-1 ^{[15]D5[18]B3b}. Patients with ECOG ≥2, who constitute a substantial proportion of the polymetastatic population, were excluded. Therefore, applicability to frail or elderly patients is uncertain.
• Extensive-stage SCLC: The ASTRO SCLC guideline ^[13]A1c does not recommend SBRT for polymetastatic SCLC outside clinical trials. The ongoing RISE trial (NCT05533528) is specifically evaluating RT (including possible SBRT) for ED-SCLC with up to 10 metastases, but results are pending ^[16]D5. Currently, no high-quality evidence supports SBRT in this histology.
• Immunotherapy combinations: Two phase II trials (ImmunoSABR ^[15]D5 and a durvalumab + SABR study ^[14]C4) enrolled only oligometastatic patients (usually 1-5 lesions), not polymetastatic. Extrapolating their efficacy signal (HR not yet reported for polymetastatic subsets) is speculative.

Anatomic and Safety Caveats

• Central tumors: SBRT to central airways (proximal bronchial tree, esophagus, heart) carries increased risk of grade ≥3 toxicity (fistula, stenosis, bleeding) ^[20]A1c. The ASTRO early-stage NSCLC guideline advises caution and recommends fractionated regimens (e.g., 50 Gy in 5 fractions) for central locations to lower the risk ^[20]A1c. In polymetastatic disease with central thoracic lesions, dose constraints must be prioritized, potentially limiting SBRT feasibility.
• Brainstem metastases: The single case report of SBRT for SCLC brainstem metastasis achieved 20-month disease-free survival, but this is anecdotal (level 4 evidence) and does not establish safety or efficacy in a polymetastatic cohort ^[17]C4.
• Concurrent systemic therapy: In the Wang et al. study, EGFR-TKIs were continued during SBRT, with acceptable toxicity ^[18]B3b. However, combining SBRT with immunotherapy or chemotherapy may increase pneumonitis and esophagitis rates, especially for large PTV volumes ^[15]D5. The optimal sequencing and timing are not defined for polymetastatic patients.

Guideline Stance

Current ASTRO guidelines do not recommend SBRT for polymetastatic (vs oligometastatic) lung cancer outside clinical trials or registries ^{[13]A1c[20]A1c}. The evidence is strongest for EGFR-mutant NSCLC with polymetastatic disease, where retrospective data suggest a PFS benefit (median PFS 17.8 vs 13.4 months; HR 0.65, 95% CI 0.47-0.89; NNT = 5 to prevent one progression at 12 months ^[18]B3b), but this is from a single-center propensity-matched analysis with limited follow-up.

Pearl: The evidence for SBRT in polymetastatic lung cancer is indirect, based on oligometastatic or EGFR-mutant subsets, and does not extend to extensive-stage SCLC; high-quality trials with polymetastatic-specific endpoints are urgently needed.

Emerging Evidence and Pivotal Trials

For polymetastatic NSCLC, the foundational trials that established the current standard, such as NRG-LU002 and SARON, have reported null or negative results for SBRT as an adjunct to systemic therapy. The question of whether SBRT adds clinical benefit in this population is therefore currently unresolved.

Synchronous SABR plus Immunotherapy Checkpoint Inhibition

The NIVORAD trial (ALTG14/002, a randomised phase 2 study) investigated adding single-fraction SABR (18-20 Gy) to nivolumab 240 mg every 2 weeks in patients with metastatic NSCLC who had progressed after first- or second-line chemotherapy and were immunotherapy-naïve ^[11]A1b. The primary endpoint, 6-month progression-free survival, was not met, and overall survival was not improved compared to nivolumab alone ^[11]A1b. While the trial focused on patients eligible for SABR (i.e., with a suitable disease site), its null result dampens enthusiasm for unselected addition of SBRT in the post-chemotherapy setting.

Combination SABR, Chemotherapy, and Immunotherapy in Oligometastatic Disease

A multicentre phase 2 single-arm study tested durvalumab plus platinum-doublet chemotherapy followed by SABR (dose not specified) to all sites of oligometastatic disease in previously untreated stage IV NSCLC ^[14]C4. The primary endpoint was investigator-assessed PFS, and the regimen showed promising early efficacy ^[14]C4. However, this trial enrolled only patients with oligometastatic disease (typically ≤5 metastases), a population distinct from the polymetastatic group for which this question applies. Extrapolation to polymetastatic patients is not supported by current evidence.

Low-Dose Radiation as an Immunomodulator

The IHC002 trial (protocol published, randomised phase 2) is testing the combination of low-dose radiation (LDRT) plus SBRT with the PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer ^[23]D5. The rationale is that LDRT may potentiate the abscopal effect of SBRT by modulating the tumour microenvironment without increasing toxicity. This trial is ongoing, and results are awaited to determine whether this strategy might benefit the polymetastatic subgroup.

Safety Signals with Combination Therapy

Concerns about radiation-induced lung injury (RILI) remain a barrier to combining SBRT with immunotherapy in polymetastatic patients, who often have extensive intrathoracic disease. French guidelines (AFSOS-SFRO) now provide structured recommendations for the diagnosis, grading, and supportive management of RILI, which may facilitate safer treatment planning ^[21]A1c. The systematic review and meta-analysis by Wang et al. 2025 found that combining radiotherapy with immune checkpoint inhibitors did not significantly increase the risk of pneumonitis compared to radiotherapy alone (odds ratio 0.97, 95% CI 0.63 to 1.50) ^[1]A1a. NNT = not calculable from reported data. This is practice-changing: the historical fear of synergistic pneumonitis may be largely unfounded, opening the door to future trials that more aggressively combine SBRT with immunotherapy even in polymetastatic settings.

Ongoing Pivotal Trial

A key ongoing trial is the NRG-LU010 / SARON platform (comparing SBRT to all sites vs. standard systemic therapy in patients with ≤10 metastases). Its results will directly inform whether SBRT has a role in the upper end of the oligometastatic / lower polymetastatic range. No completed phase 3 trial has yet demonstrated a survival benefit for SBRT in polymetastatic lung cancer.

Pearl: Current evidence from randomised trials does not support the routine addition of SBRT to systemic therapy in polymetastatic NSCLC ^[11]A1b. Two promising avenues for future practice, low-dose radiation to boost the abscopal effect ^[23]D5 and the safety of combining SBRT with immunotherapy ^[1]A1a, are under active investigation, but practice should not change until confirmatory phase 3 data emerge.